Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 118

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Pancreatic carcinoma

Recruiting

Study on the Effect of Calcium Folinate, Gemcitabine, and Fluorouracil in Patients with Advanced Pancreatic Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Vaestra Goetalandsregionen

Prostate cancer

Recruiting

Study of Apalutamide and Radiation Therapy for Patients with Low Burden Metastatic Hormone Sensitive Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Fondazione Radioterapia Oncologica Onlus

Prostate cancer recurrent

Recruiting

Study on the Safety and Effectiveness of SpectraCure P18 System and Verteporfin for Treating Recurrent Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:SpectraCure AB (publ)

Anaplastic large cell lymphoma T- and null-cell types

Recruiting

Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Vinblastine Sulfate
  • Sponsor:GPOH gGmbH

Head and neck cancer

Recruiting

Study on Using Indocyanine Green for Detecting Residual Disease in Head and Neck Cancer Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Indocyanine Green
  • Sponsor:Institut Gustave Roussy

Hormone-dependent prostate cancer

Recruiting

Study on the Effectiveness of Triptorelin, Goserelin Acetate, and Enzalutamide in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix
  • Sponsor:UZ Leuven

Malignant melanoma

Recruiting

Study on Tranexamic Acid to Reduce Early Relapse in Melanoma Patients Undergoing Surgery

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Region Midtjylland

Metastatic malignant melanoma

Recruiting

Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Double hit lymphoma+7

Recruiting

Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Universitaet Des Saarlandes

Ewing's sarcoma

Recruiting

Study on Ewing Sarcoma Treatment with Vinorelbine and Drug Combination for Patients with Primary and Disseminated Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:GPOH gGmbH

B-cell lymphoma+1

Recruiting

Study of Pembrolizumab for Children with Advanced Melanoma or PD-L1 Positive Solid Tumors and Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Peripheral T-cell lymphoma unspecified

Recruiting

Study on the Benefits of Autologous Stem Cell Transplantation for Patients with Peripheral T-cell Lymphoma Using Etoposide and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:LYSARC

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.